Skip to main content

Women's Health

Discovery Services

Select Service Type

OSTEOPOROSIS

  • Osteoblast proliferation assayDRF/CB/WH-01

    Osteoblast proliferation assay to evaluate bone health using osteoblasts (MG-63) cells.

    • Cell Model

      Osteoblasts (MG-63)

    • End Point

      increased proliferation

    • Reference Drugs

      Calcitriol/ Rutin

    • Relevance

      Bone Health
  • Alkaline Phosphatase (ALP) activityDRF/CB/WH-02

    Alkaline Phosphatase (ALP) activity to evaluate bone health/Estrogenic activity using Osteoblasts (MG-63) cells.

    • Cell Model

      Osteoblasts (MG-63)

    • End Point

      ALP activity

    • Reference Drugs

      Calcitriol/ Rutin

    • Relevance

      Bone Health/Estrogenic activity
  • Collagen synthesis in osteoblastsDRF/CB/WH-03

    Collagen synthesis in osteoblasts to evaluate Bone Health using Osteoblasts (MG-63)cells.

    • Cell Model

      Osteoblasts (MG-63)

    • End Point

      Collagen levels

    • Reference Drugs

      Calcitriol/ Rutin

    • Relevance

      Bone Health
  • Calcium deposition in osteoblastsDRF/CB/WH-04

    Calcium deposition in osteoblasts to evaluate Bone Health/osteoporosis using Osteoblasts (MG-63)cells.

    • Cell Model

      Osteoblasts (MG-63)

    • End Point

      Calcium deposits by alizarin staining

    • Reference Drugs

      Calcitriol/ Rutin

    • Relevance

      Bone Health/osteoporosis
  • Cytokines/MMPs inhibition in osteoblastsDRF/CB/WH-05

    Cytokines/MMPs inhibition in osteoblasts to evaluate Bone Health/osteoporosis using Osteoblasts (MG-63)cells.

    • Cell Model

      Osteoblasts (MG-63)

    • End Point

      Inhibition of cytokines as compared to damage

    • Reference Drugs

      Calcitriol/ Rutin

    • Relevance

      Bone Health/osteoporosis
  • Biomarker analysis by multiplexingDRF/CB/WH-06

    Biomarker analysis by multiplexing to evaluate Bone Health/osteoporosis using Osteoblasts (MG-63)cells.

    • Cell Model

      Osteoblasts (MG-63)

    • End Point

      Modulation of key biomarkers involved

    • Reference Drugs

      Calcitriol/ Rutin

    • Relevance

      Bone Health/osteoporosis

ENDOMETRIOSIS

  • Proliferation of endometrial cells line (Ishikawa)DRF/CB/WH-07

    Proliferation of endometrial cells line (Ishikawa) to evaluate Endometriosis using Endometrial cells (Ishikawa).

    • Cell Model

      Endometrial cells (Ishikawa)

    • End Point

      increased proliferation

    • Reference Drugs

      b-estradiol

    • Relevance

      Endometriosis
  • ALP (Alkaline phosphatase) activity in endometrial cells line (Ishikawa)DRF/CB/WH-08

    ALP (Alkaline phosphatase) activity in endometrial cells line (Ishikawa) to evaluate Endometriosis using Endometrial cells (Ishikawa).

    • Cell Model

      Endometrial cells (Ishikawa)

    • End Point

      ALP activity

    • Reference Drugs

      b-estradiol

    • Relevance

      Endometriosis
  • Cytokines inhibition endometrial cells line (Ishikawa)DRF/CB/WH-09

    Cytokines inhibition endometrial cells line (Ishikawa) to evaluate Endometriosis using Endometrial cells (Ishikawa).

    • Cell Model

      Endometrial cells (Ishikawa)

    • End Point

      Inhibition of cytokines as compared to damage

    • Reference Drugs

      b-estradiol

    • Relevance

      Endometriosis
  • NO, PGE2 levels in endometrial cells line (Ishikawa)DRF/CB/WH-10

    NO, PGE2 levels in endometrial cells line (Ishikawa) to evaluate Endometriosis using Endometrial cells (Ishikawa).

    • Cell Model

      Endometrial cells (Ishikawa)

    • End Point

      Modulation of NO & PGE2 involved

    • Reference Drugs

      b-estradiol

    • Relevance

      Endometriosis
  • Estrogenic Activity Using Ovariectomized and Normal (Non-ovariectomized) Female Wistar/SD RatsPCY/WH-01

    Estrogenic activity using ovariectomized and non-ovariectomized female rats, assessing uterus weight, estrogen level, and uterus histology.

    • Animal Model

      Wistar/SD Rats

    • End Point

      Uterus weight, Histology of uterus, Estrogen level etc.

    • Reference Drugs

      `--
  • Effect of test compound on letrozole induced polycystic Ovary syndrome (PCOS) PCY/WH-02

    Letrozole-induced polycystic ovary syndrome (PCOS) model in rats, measuring lipid profile, testosterone, progesterone, LH, FSH, and ovary histology.

    • Animal Model

      Wistar/ SD Rats

    • End Point

      Lipid Profile, Testosterone, Progesterone, LH, FSH, Antioxidants (SOD, Catalase), Oestrus Cycle, Histopathology of Ovary

    • Reference Drugs

      Clomiphene Citrate
  • Anti-osteoporotic activity using ovariectomy modelPCY/WH-03

    Anti-osteoporotic activity using ovariectomy model in rats, measuring plasma TSH, estrogen levels, antioxidant levels, and mineral content.

    • Animal Model

      Wistar/SD Rats

    • End Point

      Plasma TSH, Estrogen levels, Antioxidant, Minerals

    • Reference Drugs

      `--